<DOC>
	<DOCNO>NCT00767260</DOCNO>
	<brief_summary>There evidence non-immune mediate inflammatory pathway cell damage occur vitro human islet upon hyperglycemia type 2 diabetes mellitus . Autologous stem cell therapy emerge set therapy show promise low side effect profile . hypothesize infusion mononuclear cell buffy coat obtain bone marrow might provide multiple signal regeneration inflammation-induced lesion recovery local tissue , effect might maximize intra-arterial pancreatic infusion angiography combination hyperbaric oxygen therapy . This trail include forego sub-trial investigate feasibility safety novel method massive bone marrow collection . The traditional BM collecting procedure unfavorable yield minor bone marrow . Studies show physiological exercise increase bone marrow blood flow , might facilitate BM collection . We plan include total 60 patient type 2 diabetes randomly assign either control group exercise group ( n =30 ) . The patient exercise group exercise 30 minute operation . All patient underwent routine surgical care . The collected BM volume , operation time , collect speed , puncture time pain score operation record . Bone marrow sample test CD34+ flow cytometry whole blood cell count .</brief_summary>
	<brief_title>Bone Marrow Mononuclear Cell Hyperbaric Oxygen Therapy Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Male female patient age 40 65 year age . Ability provide write informed consent . Mentally stable able comply procedure study protocol . Clinical history compatible type 2 diabetes ( T2DM ) define Expert Committee Diagnosis classification Diabetes Mellitus Onset T2DM disease ≥ 35 year age . T2DM duration ≥ 3 ≤ 20 year time enrollment . Basal Cpeptide 0.32.0 ng/mL HbA1c ≥ 7.5 ≤ 12 % standard medical therapy ( SMT ) . Patients must treat SMT minimum 4 month prior randomization . Insulin dose metformin dos stable 3 month prior randomization . HbA1c ≥ 7.5 ≤ 9.5 % time randomization . Total insulin daily dose ( TDD ) time randomization exceed 1.0 units/day/kg BMI &gt; 35 kg/m2 . Insulin requirement &gt; 100 U/day . HbA1c &gt; 9.5 % . ( time randomization ) Creactive protein ( hsCRP ) &gt; 3.00 Uncontrolled blood Pressure : SBP &gt; 160 mmHg DBP &gt; 100 mmHg time randomization . Evidence renal dysfunction , serum creatinine &gt; 1.5 mg/dl ( male ) 1.4 mg/dl ( female ) . Proteinuria &gt; 300 mg/day Evidence cardiovascular disease , exist congestive cardiac failure physical exam and/or acute coronary syndrome past 6 month . For female participant : Positive pregnancy test , presently breastfeed , unwillingness use effective contraceptive measure duration study . For male participant : intent procreate 3 month intervention unwillingness use effective measure contraception . Oral contraceptive , Norplant® , DepoProvera® , barrier device spermicide acceptable contraceptive method ; condom use alone acceptable Active infection include hepatitis C , HIV , TB determine positive skin test clinical presentation , treatment suspect TB . Positive test acceptable associate history previous vaccination absence sign active infection . Positive test otherwise acceptable , even absence active infection time evaluation Known active alcohol substance abuse include cigarette/cigar smoking Baseline Hgb low limit normal local laboratory ; lymphopenia ( &lt; 1,000/L ) , neutropenia ( &lt; 1,500/L ) , thrombocytopenia ( platelet &lt; 100,000/L ) . A history Factor V deficiency coagulopathy define INR &gt; 1.5 , PTT &gt; 40 , PT &gt; 15 . Any coagulopathy medical condition require longterm anticoagulant therapy ( e.g. , warfarin ) transplantation ( lowdose aspirin treatment allow ) patient INR &gt; 1.5 . Acute chronic pancreatitis . Symptomatic peptic ulcer disease . Hyperlipidemia despite medical therapy ( fast LDL cholesterol &gt; 130 mg/dl , treat untreated ; and/or fast triglyceride &gt; 200 mg/dl ) . Receiving treatment medical condition require chronic use systemic steroid . Symptomatic cholecystolithiasis . Use investigational agent within 4 week enrollment . Admission hospital reason 14 day prior enrollment ( sign consent ) . Presence active proliferative diabetic retinopathy macular edema Any malignancy Abnormal liver function &gt; 1.5 x ULN Abdominal aortic aneurysm History cerebrovascular accident Any patient acute subacute decompensation diabetes Any acute chronic infectious condition criterion investigator would risk patient . Subjects hypoproteinemia , cachexia terminal state Subjects history anorexia/bulimia Subjects respiratory insufficiency Subjects history chronic sinusitis ( sinusitis last 8 week past year ) recurrent acute sinusitis ( sinusitis last 4 week four time past year . Any contraindication hyperbaric oxygen treatment Subjects treat medication could interfere outcome study : Sulfonylureas , Thiazolidinediones glucagon like peptide 1 ( GLP1 ) analogue ( Exenatide , Byetta ) , Pramlintide ( Amylin ) , Dipeptidylpeptidase IV ( DPPIV ) inhibitor ( i.e . Sitagliptin , Januvia ) Any medical condition , opinion investigator , interfere safe completion trial .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>type 2 diabetes mellitus</keyword>
	<keyword>bone marrow mononuclear cell</keyword>
	<keyword>hyperbaric oxygen therapy</keyword>
</DOC>